Where: Espinho, Portugal
Currently living in: Brussels, Belgium since June 2007.
Previously in Lausanne, Switzerland (2003-2007); Paris, France (2000-2003) and Boston, USA (1999-2000).
Highschool Diploma in Biotechnology in 1991, Colégio Internato dos Carvalhos.
University degree in Biology by University of Oporto, Faculty of Science, Portugal (1995).
Post-graduate student of the GABBA doctoral program,University of Oporto.
PhD in Human Tumor Immunology, University of Oporto, Faculty of Medicine, Porto, Portugal (March 2003).
PhD was done under supervision of Dr. Kostas Kosmatopoulos (INSERM U487) and
Dr. Angelo A. Cardoso (Dana-Farber Cancer Research).
Post-doctoral fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland
from May 2003 to October 2005, in the lab of Dr. Pedro Romero.
Post-doctoral fellow the Institute Suisse de la Recherche Expérimentale sur le Cancer, Switzerland
from Novenber 2005 to May 2007, in the lab of Dr. Frédéric Lévy.
Post-doctoral fellow at the Université Cathólique de Louvain, Institut de Pathologie Cellulaire Christian de Duve, Belgium since June 2007, in the lab of Prof. Pierre Coulie.
Published Research Manuscripts:
Alves PM,
Lévy N, Stevenson BJ, Bouzourene H, Theiler G, Bricard G, Viatte S,
Ayyoub M, Vuilleumier H, Givel JC, Rimoldi D, Speiser DE, Jongeneel CV,
Romero PJ, Lévy F.
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer.
Cancer Immun. 2008 Jun 27;8:11.(abstract).
Alves PM, Viatte S, Fagerberg T, Michielin
O, Bricard G, Bouzourene H,
Vuilleumier H, Kruger T, Givel JC, Levy F, Speiser DE, Cerottini JC,
Romero P.
Immunogenicity of the
carcinoembryonic antigen derived
peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Cancer Immunol Immunother.
2007 Nov;56(11):1795-805(abstract).
Frédéric Lévy, Sara Colombetti, Jozef Janda, Laurence Chapatte, Pedro Alves, Javier Garcia Casado, Nicole Lévy and Anne-Lise Peitrequin
Factoring in antigen processing in designing anti-tumor T-cell vaccines
Cancer Vaccines: Challenges and Opportunities in Translation" A. Bot and M. Obrocea, eds. (New York: Informa Healthcare), submitted
Alves PM, Viatte S, Fagerberg T, Michielin O, Bricard G, Bouzourene H, Vuilleumier H, Kruger T, Givel JC, Levy F, Speiser DE, Cerottini JC, Romero P.
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Cancer Immunol Immunother. 2007 Nov;56(11):1795-805(abstract).
Faure O, Graff-Dubois S, Alves PM, Cornet S, Duffour MT, Scardino A, Gross DA, Miconnet I, Salcedo M, Chouaib S, Lemonnier FA, Abastado JP, Kosmatopoulos K.
Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.
Oncol Rep. 2007 Mar;17(3):679-85 (abstract).
Viatte S, Alves PM, Romero P.
Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.
Immunol Cell Biol. 2006 Jun;84(3):318-30 (abstract).
Alves PM, Levy N, Bouzourene H, Viatte S, Bricard G, Ayyoub M, Vuilleumier H, Givel JC, Halkic N, Speiser DE, Romero P, Levy F.
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.
Cancer Immunol Immunother. 2007 Jun;56(6):839-47(abstract, pdf)
Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K.
STEAP, a prostate tumor antigen, is a target of human CD8(+) T cells.
Cancer Immunol Immunother. 2006 Dec;55(12):1515-23(abstract ,pdf)
Migliaccio M, Alves PM, Romero P, Rufer N.
Distinct Mechanisms Control Human Naive and Antigen-Experienced CD8+ T Lymphocyte Proliferation.
J Immunol. 2006 Feb 15;176(4):2173-82.(abstract, pdf)
Michielin O, Blanchet JS, Fagerberg T, Valmori D, Rubio-Godoy V, Speiser D, Ayyoub M, Alves P, Luescher I, Gairin JE, Cerottini JC, Romero P.
Tinkering with nature: the tale of optimizing peptide based cancer vaccines.
Cancer Treat Res. 2005;123:267-91. Review.(abstract ,pdf)
Haining WN, Anderson DG, Little SR, von Bergwelt-Baildon MS, Cardoso AA, Alves P, Kosmatopoulos K, Nadler LM, Langer R, Kohane DS.
pH-triggered microparticles for peptide vaccination.
J Immunol. 2004 Aug 15;173(4):2578-85. (abstract, pdf)
Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K.
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
J Clin Invest. 2004 Feb;113(3):425-33. (abstract, pdf)
Faure O, Graff-Dubois S, Bretaudeau L, Derre L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K.
Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes.
Int J Cancer. 2004 Mar 1;108(6):863-70. (abstract, pdf)
Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K.
EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.
Cancer Res. 2003 Dec 1;63(23):8476-80. (abstract, pdf)
Scardino A, Correale P, Firat H, Pellegrini M, Kosmatopoulos K, Opolon P, Alves P, Zurbriggen R, Gluck R, Lemonnier FA, Francini G, Cusi MG.
In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse.
Br J Cancer. 2003 Jul 7;89(1):199-205. (abstract)
Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K.
Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
J Immunol. 2002 Jul 1;169(1):575-80. (abstract, pdf)
Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K.
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1;168(11):5900-6. (abstract, pdf)
Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K.
Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors.
Eur J Immunol. 2001 Nov;31(11):3261-70. (abstract, pdf)
Alves P, Soares P, Fonseca E, Sobrinho-Simoes M.
Papillary Thyroid Carcinoma Overexpresses Fully and Underglycosylated Mucins Together with Native and Sialylated Simple Mucin Antigens and Histo-Blood Group Antigens.
Endocr Pathol. 1999 Winter;10(4):315-324. (abstract)
Alves P, Soares P, Rossi S, Fonseca E, Sobrinho-Simoes M.
Clinicopathologic and Prognostic Significance of the Expression of Mucins, Simple Mucin Antigens and Histo-Blood Group Antigens in Papillary Thyroid Carcinoma.
Endocr Pathol. 1999 Winter;10(4):305-313. (abstract)
Carvalho F, David L, Aubert JP, Lopez-Ferrer A, De Bolos C, Reis CA, Gartner F, Peixoto A, Alves P, Sobrinho-Simoes M.
Mucins and mucin-associated carbohydrate antigens expression in gastric carcinoma cell lines.
Virchows Arch. 1999 Nov;435(5):479-85. (abstract, pdf)
home - photography - my Suzuki - my Protocols - my Links